Joanne Holland
Chief Tech/Sci/R&D Officer at CONDUIT PHARMACEUTICALS INC.
Joanne Holland active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 18/03/2024 | - |
Career history of Joanne Holland
Former positions of Joanne Holland
| Companies | Position | Start | End |
|---|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - | 30/05/2021 |
| Chief Tech/Sci/R&D Officer | - | 30/05/2021 | |
| NUFORMIX PLC | Director/Board Member | 31/12/2007 | 30/05/2021 |
| Chief Tech/Sci/R&D Officer | 31/12/2007 | 23/05/2021 | |
| Founder | 31/12/2007 | 30/05/2021 |
Training of Joanne Holland
| University of Leeds | Doctorate Degree |
Statistics
International
| United Kingdom | 4 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Joanne Holland
- Experience